SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as a significant analyst downgrade has intensified market debate around its valuation and future prospects. Many in the community are interpreting the price action as institutional maneuvering to acquire shares, citing the company's critical role in AI server infrastructure and rapid revenue expansion. Despite ongoing discussions about profitability and governance, investors are weighing SMCI's essential position in the AI sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with strong community buzz fueled by a recent positive analyst rating and high short interest, igniting speculation of a potential squeeze. Investors are keenly anticipating announcements from the ongoing J.P. Morgan Healthcare Conference regarding new partnerships, strategic updates, and the broader application of its Matrix-M platform, amidst ongoing discussions about management performance.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively trending as it pivots from Reality Labs layoffs towards a massive AI infrastructure buildout, highlighted by new "Meta Compute" initiatives and significant nuclear energy deals to power future data centers. This strategic shift is fueling intense debate, with some investors bearish on current spending and predicting further declines, while others view the moves as a fundamental re-rating opportunity and an attractive dip to buy for long-term AI-driven growth.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is sparking significant discussion as investors navigate notable price volatility, often attributed to ongoing CEO stock sales and perceived market manipulation. Despite these headwinds, many remain highly bullish on PATH's robust financial position, recent GAAP profitability, and its strategic leadership in the burgeoning Agentic AI space, amplified by its S&P MidCap 400 inclusion and new leveraged ETF.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending following the appointment of a new Chief Commercial Officer and the completion of enrollment in its VK2735 maintenance study, ahead of the J.P. Morgan Healthcare Conference. These developments have fueled a polarized debate, with some investors seeing a strengthening position for commercialization or strategic partnership in the competitive obesity market. However, others view the moves as a signal against an imminent buyout, coupled with ongoing concerns about stock manipulation and underperformance compared to sector peers.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is heavily discussed following its pledge to bear the electricity costs for new AI data centers, a move seen by some as bullish for accelerating infrastructure growth. Despite this, community sentiment is sharply divided, with many lamenting the stock's recent underperformance compared to other major tech companies while others view current levels as a prime accumulation opportunity for its long-term AI and cloud dominance.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl (RVYL) is experiencing intense community interest, primarily fueled by its impending merger with Roundtable to form a Web3 digital media platform with a Bitcoin treasury. The stock's notably low float and high short interest are driving widespread speculation of a significant short squeeze, with investors also closely watching progress on Nasdaq compliance and the resolution of prior litigation.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

AHMA is experiencing significant momentum, driven by its extremely low public float as a recent IPO, sparking intense discussion about a potential short squeeze. The community is actively debating its trajectory, with many speculating on substantial price targets by drawing parallels to past low-float runners, while others urge caution regarding its high volatility. Amidst the speculative fervor, some traders are also highlighting the company's underlying business, focusing on its scalable energy solutions for the healthcare sector.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following its earnings report, which, despite surpassing expectations, led to a stock decline as investors focused on elevated expectations, a substantial reserve build for the Apple Card transfer, and broader credit market concerns. The community is actively debating the potential impact of a proposed cap on credit card interest rates, adding another layer of uncertainty for the banking sector. Jamie Dimon's cautious economic outlook further contributes to the conversation around financial stability.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending amid political proposals for a 10% cap on credit card interest rates, sparking widespread debate about its potential impact. While some investors fear a significant stock decline, many in the community view this as an overreaction and a buying opportunity, emphasizing that Visa primarily profits from transaction fees and not direct interest charges. The broader discussion highlights Visa's robust global network and ongoing initiatives in digital payments and stablecoins as key long-term growth drivers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG

Bright Minds Biosciences (NASDAQ:DRUG) reported top-line results from an open-label Phase 2 breakthrough study evaluating BMB-101 in adults with highly refractory absence seizures and developmental...

Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00

BTIG Research upped their price objective on Bright Minds Biosciences from $72.00 to $147.00 and gave the stock a "buy" rating in a research note on Tuesday...

Bright Minds Biosciences (NASDAQ:DRUG) Hits New 12-Month High - What's Next?

Bright Minds Biosciences (NASDAQ:DRUG) Sets New 52-Week High - Time to Buy...

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

Equity

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.


Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.7% - Time to Sell?

Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.7% - Should You Sell...

Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)

Chardan Capital reiterated a "buy" rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a research note on Friday...

HC Wainwright Has Negative Outlook for DRUG Q1 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Bright Minds Biosciences in a research report issued on...

Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% Higher - Here's Why

Bright Minds Biosciences (NASDAQ:DRUG) Trading Up 4.2% - Time to Buy...

Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading Volume - Time to Buy?

Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase - Here's What Happened...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$86.96
Prev Close	$86.75
Open	$88.83
Dividend Yield	0.00%
50-Day Moving Average	$72.49
Beta	0.97
Avg. Volume	180,254.23
PE Ratio	-71.80

52-Week High	$123.75
52-Week Low	$23.18
Market Capitalization	$690.49M
EPS (Annual)	-$1.27
Price to Book	11.48
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRUG News

DRUGBright Minds Biosciences Inc